Early Insights From a Pharmacogenomic-Enriched Comprehensive Medication Management Program Implementation in an Adult Employee Population

Abstract

Objectives: The aims of the study are to assess adoption of a pharmacogenomicenriched comprehensive medication management program in a self-insured employer setting and to better understand medication risks that affect employees. Methods: Employees were identified to be at high risk of medication mismanagement and were subsequently provided with a program and process to improve their health. DNA testing, a clinical decision support system, and pharmacists were used to identify medication safety and effectiveness issues and to recommend appropriate changes. Results: A total of 10.6% of the invited employees enrolled in the program. Actionable recommendations were suggested by pharmacists for 85.8% of employees who completed the program, averaging 5.2 recommendations per person. Conclusions: Implementation of a PGx + CMM program in a self-insured employer setting is feasible, detects risks in prescription regimens, and offers opportunities to improve medication management and reduce the burden of healthcare expenses.

Clinical and Economic Outcomes of a Pharmacogenomics-enriched Comprehensive Medication Management Program in a Self-insured Employee Population

“…The research demonstrated that 86% of employees who completed the program received actionable recommendations, averaging 5 recommendations per person. 10 The present study compared economic and clinical outcomes between participants in a PGx + CMM program with matched controls. The primary hypothesis of the study was that there is an association between the PGx + CMM intervention and changes in healthcare resource utilization (HRU) yielding reduction in medical costs as measured by claims data at 13-months post-program inception.…”